Literature DB >> 18322236

CD44 suppresses TLR-mediated inflammation.

Hidetada Kawana1, Hirokazu Karaki, Morihiro Higashi, Masaru Miyazaki, Frank Hilberg, Motoo Kitagawa, Kenichi Harigaya.   

Abstract

The cell adhesion molecule CD44, which is the major hyaluronan receptor, has been implicated in the binding, endocytosis, and metabolism of hyaluronan. Previous studies have revealed that CD44 plays crucial roles in a variety of inflammatory diseases. In recent years, TLRs, which are ancient microbial pattern recognition receptors, have been shown to initiate an innate immune response and have been linked to a variety of inflammatory diseases. The present study shows that CD44 negatively regulates in vivo inflammation mediated by TLRs via NF-kappaB activation, which leads to proinflammatory cytokine production. Furthermore, our results show that CD44 directly associates with TLR2 when stimulated by the TLR2 ligand zymosan and that the cytoplasmic domain of CD44 is crucial for its regulatory effect on TLR signaling. This study indicates that CD44 plays a protective role in TLR-mediated inflammation and is the first to demonstrate a direct association between CD44 and a TLR.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18322236     DOI: 10.4049/jimmunol.180.6.4235

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  Modulation of the local neutrophil response by a novel hyaluronic acid-binding peptide reduces bacterial burden during staphylococcal wound infection.

Authors:  Jerry C Lee; Jennifer L Greenwich; George G Zhanel; Xiaobing Han; Andrew Cumming; Laura Saward; Rachel M McLoughlin
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

2.  Exploring the activated adipogenic niche: interactions of macrophages and adipocyte progenitors.

Authors:  Yun-Hee Lee; Robert I Thacker; Brian Eric Hall; Raymond Kong; James G Granneman
Journal:  Cell Cycle       Date:  2014-01-06       Impact factor: 4.534

Review 3.  Controversial role of toll-like receptors in acute pancreatitis.

Authors:  Juan Vaz; Hamid Akbarshahi; Roland Andersson
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

Review 4.  The role of hyaluronan and the extracellular matrix in islet inflammation and immune regulation.

Authors:  Paul L Bollyky; Marika Bogdani; Jennifer B Bollyky; Rebecca L Hull; Thomas N Wight
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

5.  Effects of 4-methylumbelliferone and high molecular weight hyaluronic acid on the inflammation of corneal stromal cells induced by LPS.

Authors:  Fang Li; Peng Hao; Guangjie Liu; Weiyi Wang; Ruifang Han; Zhixin Jiang; Xuan Li
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-12-06       Impact factor: 3.117

6.  Mechanisms Mediating High-Molecular-Weight Hyaluronan-Induced Antihyperalgesia.

Authors:  Ivan J M Bonet; Dionéia Araldi; Eugen V Khomula; Oliver Bogen; Paul G Green; Jon D Levine
Journal:  J Neurosci       Date:  2020-07-14       Impact factor: 6.167

Review 7.  Rheostatic signaling by CD44 and hyaluronan.

Authors:  Ellen Puré; Richard K Assoian
Journal:  Cell Signal       Date:  2009-01-13       Impact factor: 4.315

8.  CD44 deficiency is associated with enhanced Escherichia coli-induced proinflammatory cytokine and chemokine release by peritoneal macrophages.

Authors:  Gerritje J W van der Windt; Cornelis van 't Veer; Sandrine Florquin; Tom van der Poll
Journal:  Infect Immun       Date:  2009-11-09       Impact factor: 3.441

9.  Cerebrospinal fluid proteome of patients with acute Lyme disease.

Authors:  Thomas E Angel; Jon M Jacobs; Robert P Smith; Mark S Pasternack; Susan Elias; Marina A Gritsenko; Anil Shukla; Edward C Gilmore; Carol McCarthy; David G Camp; Richard D Smith; H Shaw Warren
Journal:  J Proteome Res       Date:  2012-08-31       Impact factor: 4.466

10.  Engagement of CD44 by hyaluronan suppresses TLR4 signaling and the septic response to LPS.

Authors:  Jun Muto; Kenshi Yamasaki; Kristen R Taylor; Richard L Gallo
Journal:  Mol Immunol       Date:  2009-09-24       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.